New combo therapy aims to keep High-Risk myeloma in check

This phase 4 study tests whether adding a low dose of lenalidomide to ixazomib works better than ixazomib alone as long-term maintenance therapy for people with high-risk multiple myeloma. About 100 participants who have already completed initial treatment will be followed to see how long the cancer stays controlled and what side effects occur. The goal is to improve disease control and delay progression.